Wednesday, December 14, 2016 11:23:49 PM
Mayer Winkler
Summary
Injectable insulin has been around since 1923, but oral insulin has proven elusive to date.
Oramed Pharmaceuticals' successful Phase IIB trial for oral insulin has shown that it can be done.
The potential advantage of oral insulin is beyond the issue of convenience, as oral administration delivers insulin directly to the liver which regulates its release naturally.
This would obviate the need to chemically alter insulin in order to regulate its release molecularly.
Oramed has plenty of cash and about a 5 year runway at current burn rate.
More than 400 million individuals suffer from diabetes, or about 5.5% of the world's population. One in every five dollars spent on healthcare in the US goes towards diabetes treatment. It's reached epidemic levels as global sugar intake increases, and its incidence rate keeps going up. It's also an area in which treatment options are not only limited, but terribly outdated.
Injectable insulin, which is far and away the most widely used treatment for both diabetes type I and II, has been widely available since 1923. One serious issue with injectable insulin is not that it doesn't work, but that it cannot be naturally regulated by the human body. Insulin directly to the blood needs to be regulated by the user in combination with various technological release modulators that chemically alter the insulin in order to make it either fast or slow-acting, depending on the user's choice. In healthy non-diabetics by contrast, insulin is delivered through the portal vein directly to the liver, which regulates its release and activation naturally.
Recent ORMP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:06:24 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/16/2024 08:42:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:05:24 PM
- Oramed Letter to Shareholders • PR Newswire (US) • 06/26/2024 01:05:00 PM
- Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 06/20/2024 11:32:05 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/20/2024 11:30:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 09:28:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 09:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:00:27 PM
- Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation • GlobeNewswire Inc. • 03/19/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:42:26 PM
- Oramed Letter to Shareholders • PR Newswire (US) • 02/20/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:43:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:41:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:39:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:37:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:36:18 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM